Emerging retatrutide, a dual -action treatment targeting simultaneously GLP-1 and GIP receptors, is sparking considerable interest within the weight loss community. Early clinical research have shown substantial reductions in overall size and advancements in health markers for people with excess weight . Scientists believe this novel approach could